Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment

This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid‐β1–42, tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost‐effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add‐on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre‐ and post‐biomarker counseling.

• Publication year

  2017

• Venue

  Alzheimer's & Dementia

• Publication date

  2017-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jalz.2016.09.009PMID 28341066
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia

  2017influential reference
• Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study

  2016cited by this paper
• Use of amyloid-PET to determine cutpoints for CSF markers

  2016cited by this paper
• CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.

  2016cited by this paper
• Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.

  2015cited by this paper
• The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

  2015cited by this paper
• Cerebrospinal Fluid β-Amyloid1–42 Levels in the Differential Diagnosis of Alzheimer’s Disease—Systematic Review and Meta-Analysis

  2015cited by this paper
• A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.

  2015cited by this paper
• Benchmarking biomarker‐based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem

  2015cited by this paper
• Rate of cognitive decline in relation to sex after 60 years‐of‐age: A systematic review

  2014cited by this paper
• The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

  2014cited by this paper
• Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

  2014cited by this paper
• Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).

  2014cited by this paper
• Improving CSF Biomarkers’ Performance for Predicting Progression from Mild Cognitive Impairment to Alzheimer’s Disease by Considering Different Confounding Factors: A Meta-Analysis

  2014cited by this paper
• Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

  2014cited by this paper
• Cost-Effectiveness of the Use of Biomarkers in Cerebrospinal Fluid for Alzheimer's Disease

  2014cited by this paper
• Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.

  2014cited by this paper
• Health economic evaluation of treatments for Alzheimer′s disease: impact of new diagnostic criteria

  2014cited by this paper
• Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

  2014cited by this paper
• Mild cognitive impairment: a concept in evolution

  2014cited by this paper
• Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia

  2013cited by this paper
• Treatment for mild cognitive impairment: systematic review

  2013cited by this paper
• Making sense of nonsense: experiences of mild cognitive impairment.

  2013cited by this paper
• Age and diagnostic performance of Alzheimer disease CSF biomarkers

  2012cited by this paper
• EFNS‐ENS Guidelines on the diagnosis and management of disorders associated with dementia

  2012cited by this paper
• Cholinesterase inhibitors for mild cognitive impairment.

  2012cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Understanding the medical and nonmedical value of diagnostic testing.

  2010cited by this paper
• Biomarkers as Predictors for Conversion from Mild Cognitive Impairment to Alzheimer-Type Dementia: Implications for Trial Design

  2010cited by this paper
• EFNS guidelines for the diagnosis and management of Alzheimer’s disease

  2010cited by this paper
• CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer’s disease: a meta-analysis of 51 studies

  2009cited by this paper
• Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease

  2009cited by this paper
• Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies

  2009cited by this paper
• Grading quality of evidence and strength of recommendations for diagnostic tests and strategies.

  2009cited by this paper
• Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease

  2009cited by this paper
• Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

  2009cited by this paper
• Rate of progression of mild cognitive impairment to dementia – meta‐analysis of 41 robust inception cohort studies

  2009cited by this paper
• Additional Patient Outcomes and Pathways in Evaluations of Testing

  2009cited by this paper
• Grading quality of evidence and strength of recommendations for diagnostic tests and strategies

  2008cited by this paper
• Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature

  2008cited by this paper
• Mild cognitive impairment: coping with an uncertain label

  2008cited by this paper
• Cholinesterase Inhibitors in Mild Cognitive Impairment: A Systematic Review of Randomised Trials

  2007cited by this paper
• Impact of cognitive impairment on mild dementia patients and mild cognitive impairment patients and their informants

  2006cited by this paper
• Making sense of mild cognitive impairment: a qualitative exploration of the patient's experience.

  2006cited by this paper
• Alzheimer's disease

  2006cited by this paper
• Cost‐effectiveness of 18F‐fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective

  2005cited by this paper
• Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.

  2004cited by this paper
• Cerebrospinal fluid β-amyloid1–42 and tau in control subjects at risk for Alzheimer’s disease: The effect of APOE ε4 allele

  2004cited by this paper
• Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

  2004cited by this paper
• Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2012

  2004cited by this paper
• Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004 *

  2004cited by this paper
• CSF markers for incipient Alzheimer's disease.

  2003cited by this paper
• Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment.

  2002cited by this paper
• High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

  1998cited by this paper

• Wearable EEG devices in the detection of mild cognitive impairment: a systematic review.

  2026cites this paper
• Proteome-Based Biomarkers for Alzheimer’s Disease: Old Acquisitions and Innovative Proposals

  2025cites this paper
• Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer’s disease

  2025cites this paper
• The Danish Dementia Research Centre: Integrating patient care, clinical research, and national educational services

  2025cites this paper
• Exploring Cognitive Enhancers: from neurotherapeutics to ethical and regulatory challenges: a mini review

  2025cites this paper
• AI-based staging, causal hypothesis and progression of subjects at risk of Alzheimer’s disease: a multicenter study

  2025cites this paper
• Retinal and Vascular Findings in Optical Coherence Tomography in Healthy Cognitive Patients With Alzheimer Disease Biomarkers

  2025cites this paper
• Method comparison and re-calibration of three top-used immunoassays and one LC-MS/MS assay for four core cerebrospinal fluid biomarkers of Alzheimer's disease: an explorative study for harmonization.

  2025cites this paper
• Altered tear fluid protein expression in persons with mild Alzheimer's disease in proteins involved in oxidative stress, protein synthesis, and energy metabolism

  2025cites this paper
• Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease

  2025cites this paper
• Lateralization of the Aberrant Amplitude of Low-Frequency Fluctuation within the Default Mode Network in Patients with Mild Cognitive Impairment.

  2025cites this paper
• A Speech-Based Mobile Screening Tool for Mild Cognitive Impairment: Technical Performance and User Engagement Evaluation

  2025cites this paper
• Ultrasensitive and Multiple Biomarker Discrimination for Alzheimer's Disease via Plasmonic & Microfluidic Sensing Technologies

  2024cites this paper
• Facing the new diagnostic and treatment options of Alzheimer's disease: The necessity of informed consent

  2024cites this paper
• Cognitive Intra-individual Variability in Cognitively Healthy APOE ε4 Carriers, Mild Cognitive Impairment, and Alzheimer’s Disease: a Meta-analysis

  2024cites this paper
• Counseling and disclosure practices in predictive Alzheimer's disease diagnostics: A scoping review

  2024cites this paper
• Agreement between Cerebrospinal Fluid Biomarkers, Brain 18-Fluorodeoxyglucose PET, and Clinical Diagnosis in Older Adults with Cognitive Impairment.

  2024cites this paper
• Psychological outcomes of dementia risk estimation in MCI patients: Results from the PreDADQoL project

  2024cites this paper
• Platelets and Neurodegenerative Diseases: Current Knowledge and Future Perspectives

  2024cites this paper
• The Australian Traumatic Brain Injury Initiative: Statement of Working Principles and Rapid Review of Methods to Define Data Dictionaries for Neurological Conditions

  2024cites this paper
• European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders.

  2024cites this paper
• CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab

  2023cites this paper
• Automated magnetic-bead-assisted sequential extraction technology for simultaneous detection of Aβ1-42 and Aβ1-40 in cerebrospinal fluid: An advance toward fully automated liquid chromatography-tandem mass spectrometry method.

  2023cites this paper
• Detection of Mild Cognitive Impairment Using Facial Features in Video Conversations

  2023cites this paper
• A data‐driven approach to complement the A/T/(N) classification system using CSF biomarkers

  2023cites this paper
• Ethical Issues of Primary and Secondary Dementia Prevention

  2023cites this paper
• [The controversy over early diagnosis of Alzheimer's disease: A literature review of the advantages and disadvantages].

  2023cites this paper
• Predementia Counseling

  2023cites this paper
• NEURONORMA Cognitive Battery Associations with Cerebrospinal Fluid Amyloid-β and Tau Levels in the Continuum of Alzheimer’s Disease

  2023cites this paper
• Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer's disease and synucleinopathies.

  2023cites this paper
• Robustness of CSF Aβ42/40 and Aβ42/P‐tau181 measured using fully automated immunoassays to detect AD‐related outcomes

  2023cites this paper
• Deep proteome analysis of plasma reveals novel biomarkers of mild cognitive impairment and Alzheimer’s disease: A longitudinal study

  2022cites this paper
• SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers

  2022cites this paper
• Potential value of cerebrospinal fluid α-synuclein in the identification of postoperative delirium undergoing knee/hip arthroplasty: The perioperative neurocognitive disorder and biomarker lifestyle study

  2022cites this paper
• The cognitive performance in the Phototest is predictor of biological markers of Alzheimer's disease

  2022cites this paper
• The Key Role of Magnetic Resonance Imaging in the Detection of Neurodegenerative Diseases-Associated Biomarkers: A Review

  2022cites this paper
• A Metallomic Approach to Assess Associations of Plasma Metal Levels with Amnestic Mild Cognitive Impairment and Alzheimer’s Disease: An Exploratory Study

  2022cites this paper
• Amyloid- β Oligomers: Multiple Moving Targets

  2022cites this paper
• Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios

  2022cites this paper
• The Road to Personalized Medicine in Alzheimer’s Disease: The Use of Artificial Intelligence

  2022cites this paper
• Network-constrained technique to characterize pathology progression rate in Alzheimer’s disease

  2021influential citation
• Biomarker testing in MCI patients—deciding who to test

  2021cites this paper
• Optical Coherence Tomography in Patients with Alzheimer’s Disease: What Can It Tell Us?

  2021cites this paper
• CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment

  2021cites this paper
• Biomarker-Based Risk Prediction of Alzheimer’s Disease Dementia in Mild Cognitive Impairment: Psychosocial, Ethical, and Legal Aspects

  2021cites this paper
• Pyroptosis executive protein GSDMD as a biomarker for diagnosis and identification of Alzheimer’s disease

  2021cites this paper
• 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

  2021cites this paper
• Comparison of the clinical impact of 2-[18F]FDG-PET and cerebrospinal fluid biomarkers in patients suspected of Alzheimer’s disease

  2021cites this paper
• Fluid Biomarkers in Clinical Trials for Alzheimer’s Disease: Current and Future Application

  2021cites this paper
• Use of Alzheimer’s Disease Cerebrospinal Fluid Biomarkers in A Tertiary Care Memory Clinic

  2021influential citation
• A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

  2021cites this paper
• Use of a panel of four microRNAs in CSF as a predicted biomarker for postoperative neoangiogenesis in moyamoya disease

  2021cites this paper
• Cobalt induces neurodegenerative damages through Pin1 inactivation in mice and human neuroglioma cells.

  2021cites this paper
• The approval of a disease-modifying treatment for Alzheimer’s disease: impact and consequences for the nuclear medicine community

  2021cites this paper
• Soluble APP-α and APP-β in cerebrospinal fluid as potential biomarkers for differential diagnosis of mild cognitive impairment

  2021cites this paper
• CSF in Epileptic Prodromal Alzheimer's Disease: No Diagnostic Contribution but a Pathophysiological One

  2021cites this paper
• Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery

  2021cites this paper
• A Computational Monte Carlo Simulation Strategy to Determine the Temporal Ordering of Abnormal Age Onset Among Biomarkers of Alzheimer's Disease

  2021cites this paper
• Diagnosis and Treatment for Mild Cognitive Impairment: A Systematic Review of Clinical Practice Guidelines and Consensus Statements

  2021cites this paper
• Diagnosi clinicolaboratoristica della malattia di Alzheimer

  2021cites this paper
• Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer’s Disease

  2021cites this paper
• Elderly Patients with Mild Cognitive Impairment Exhibit Altered Gut Microbiota Profiles

  2021cites this paper
• Cerebrospinal fluid neurofilament light predicts the rate of executive function decline in younger-onset dementia.

  2021cites this paper
• Bipartite graph modeling of Alzheimer’s disease and its early automated discrimination through region-based level set algorithm and support vector machine in magnetic resonance brain images

  2021cites this paper
• Diagnostic clinicobiologique de la maladie d’Alzheimer

  2021cites this paper
• EB_A_235238 1..20

  2021cites this paper
• Biomarker Testing: Piercing the Fog of Alzheimer’s and Related Dementia

  2020cites this paper
• European Academy of Neurology/European Alzheimer’s Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment

  2020cites this paper
• The process of disclosing a diagnosis of dementia and mild cognitive impairment: A national survey of specialist physicians in Denmark

  2020cites this paper
• Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer’s Disease

  2020cites this paper
• Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts.

  2020cites this paper
• Interest of biological biomarkers in the diagnostic approach of neurocognitive disorders in the elderly.

  2020cites this paper
• Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer's disease: a 24-month follow-up study.

  2020cites this paper
• Früherkennung der Alzheimer-Krankheit und Demenzprädiktion bei Patienten mit leichter kognitiver Störung

  2020cites this paper
• Sex-specific Association of Subjective Cognitive Decline and Apolipoprotein E ε4 Genotype with Risk of Incident Mild Cognitive Impairment

  2020cites this paper
• Periodontal disease as a possible cause for Alzheimer's disease.

  2020cites this paper
• Prognostic value of complementary biomarkers of neurodegeneration in a mixed memory clinic cohort

  2020cites this paper
• Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia

  2020cites this paper
• Dementia prevention, intervention, and care: 2020 report of the Lancet Commission

  2020cites this paper
• Circulating Exosome microRNAs as Diagnostic Biomarkers of Dementia

  2020cites this paper
• Diagnostic Impact of Cerebrospinal Fluid Biomarkers in Atypical Dementias in Canada

  2020influential citation
• Biomarker counseling, disclosure of diagnosis and follow‐up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey

  2020cites this paper
• CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment.

  2020cites this paper
• Pet-amyloid after inconclusive cerebrospinal fluid biomarkers in clinical practice. is it necessary to duplicate procedures?

  2020cites this paper
• An Ensemble-Learning Based Application to Predict the Earlier Stages of Alzheimer’s Disease (AD)

  2020cites this paper
• State of the science on mild cognitive impairment (MCI)

  2019cites this paper
• Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project

  2019cites this paper
• Alzheimer's disease.

  2019cites this paper
• Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment.

  2019cites this paper
• The Italian INTERCEPTOR Project: From the Early Identification of Patients Eligible for Prescription of Antidementia Drugs to a Nationwide Organizational Model for Early Alzheimer’s Disease Diagnosis

  2019cites this paper
• High-Throughput Mass Spectrometry Assay for Quantifying β-Amyloid 40 and 42 in Cerebrospinal Fluid.

  2019cites this paper
• Italian consensus recommendations for a biomarker‐based aetiological diagnosis in mild cognitive impairment patients

  2019cites this paper
• Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer’s Disease and Inconclusive First Biomarker

  2019cites this paper
• Early diagnosis of Alzheimer’s disease using combined features from voxel-based morphometry and cortical, subcortical, and hippocampus regions of MRI T1 brain images

  2019cites this paper
• Staging the cognitive continuum in prodromal Alzheimer's disease with episodic memory.

  2019cites this paper
• Plasma Neurofilament Light Chain Levels Are Associated With Cortical Hypometabolism in Alzheimer Disease Signature Regions.

  2019cites this paper
• Salivary biological biomarkers for Alzheimer's disease.

  2019cites this paper
• α-synuclein in the pathophysiology of Alzheimer’s disease

  2019cites this paper
• Cerebrospinal Fluid and Urinary Biomarkers of Alzheimer Disease

  2019cites this paper
• Identification d'un profil de marqueurs périphériques lié aux scores cognitifs dans le plasma et les vésicules extracellulaires durant le développement de la maladie d'Alzheimer: évolution de marqueurs liés au stress oxydatif et aux mécanismes physiopathologiques.

  2019cites this paper